摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[(E)-[(3-chloro-5-fluoropyridin-4-yl)methylidene]amino]guanidine | 1620238-04-1

中文名称
——
中文别名
——
英文名称
1-[(E)-[(3-chloro-5-fluoropyridin-4-yl)methylidene]amino]guanidine
英文别名
2-[(E)-(3-chloro-5-fluoropyridin-4-yl)methylideneamino]guanidine
1-[(E)-[(3-chloro-5-fluoropyridin-4-yl)methylidene]amino]guanidine化学式
CAS
1620238-04-1
化学式
C7H7ClFN5
mdl
——
分子量
215.617
InChiKey
FUKIDGJAUHEDGI-HSIUAXRUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    89.6
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • [EN] BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES<br/>[FR] DÉRIVÉS DE BENZYLIDÈNEGUANIDINE ET LEUR UTILISATION THÉRAPEUTIQUE POUR LE TRAITEMENT DE MALADIES LIÉES À UN MAUVAIS REPLIEMENT DE PROTÉINES
    申请人:MEDICAL RES COUNCIL
    公开号:WO2014108520A1
    公开(公告)日:2014-07-17
    The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein:R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7,OR7and NR8R9; R7, R8and R9 are each independently selected from alkyl, cycloalkyl, aralkyl,cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2,COO-alkyl,aralkyl,SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy;X and Z are each independently CR11, and Y is selected from CR11and N; and R11is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    本发明涉及一种具有以下结构的化合物(I),或其亪式和/或药用可接受的盐,其中:R1为烷基,Cl,F或Br;R2为H或F;R3从H和烷基中选择;R4从H和C(O)R6中选择;R5为H;或R4和R5连接形成一个杂环基团,该基团可以选择性地用一个或多个R10基团取代;R6从R7,OR7和NR8R9中选择;R7,R8和R9分别独立选择自烷基,环烷基,芳基,环烯基,杂环烷基和芳基,每个基团可以选择性地用一个或多个R10基团取代;每个R10独立选择自卤素,OH,CN,NO2,COO-烷基,芳基,SO2-烷基,SO2-芳基,COOH,CO-烷基,CO-芳基,NH2,NH-烷基,N(烷基)2,CF3,烷基和烷氧基;X和Z各自独立为CR11,Y从CR11和N中选择;R11为H或F;用于治疗与蛋白质错误折叠应激相关的疾病,特别是与错误折叠蛋白质积累相关的疾病。
  • Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
    申请人:GUEDAT Philippe
    公开号:US20160046589A1
    公开(公告)日:2016-02-18
    The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R 1 is alkyl, Cl, F or Br; R 2 is H or F; R 3 is selected from H and alkyl; R 4 is selected from H and C(O)R 6 ; R 5 is H; or R 4 and R 5 are linked to form a heterocyclic group which is optionally substituted with one or more R 10 groups; R 6 is selected from R 7 , OR 7 and NR 8 R 9 ; R 7 , R 8 and R 9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R 10 groups; each R 10 is independently selected from halogen, OH, CN, NO 2 , COO-alkyl, aralkyl, SO 2 -alkyl, SO 2 -aryl, COOH, CO-alkyl, CO-aryl, NH 2 , NH-alkyl, N(alkyl) 2 , CF 3 , alkyl and alkoxy; X and Z are each independently CR 11 , and Y is selected from CR 11 and N; and R 11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    本发明涉及式(I)的化合物,或其互变异构体和/或药学上可接受的盐,其中:R1为烷基,;R2为氢或;R3选自氢和烷基;R4选自氢和C(O)R6;R5为氢;或R4和R5连接形成一个杂环基团,该杂环基团可选地被一个或多个R10基团取代;R6选自R7,OR7和NR8R9;R7,R8和R9各自独立地选自烷基,环烷基,芳基烷基,环烯基,杂环基和芳基,每个基团可选地被一个或多个R10基团取代;每个R10各自独立地选自卤素,羟基,基,硝基,COO-烷基,芳基烷基,SO2-烷基,SO2-芳基,COOH,CO-烷基,CO-芳基,NH2,NH-烷基,N(烷基)2,CF3,烷基和烷氧基;X和Z各自独立地为CR11,Y选自CR11和N;R11为氢或;用于治疗与蛋白质错折应激相关的疾病,特别是与错折蛋白的积累相关的疾病。
  • Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases
    申请人:Medical Research Council
    公开号:US10100020B2
    公开(公告)日:2018-10-16
    The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, wherein: R1 is alkyl, Cl, F or Br; R2 is H or F; R3 is selected from H and alkyl; R4 is selected from H and C(O)R6; R5 is H; or R4 and R5 are linked to form a heterocyclic group which is optionally substituted with one or more R10 groups; R6 is selected from R7, OR7 and NR8R9; R7, R8 and R9 are each independently selected from alkyl, cycloalkyl, aralkyl, cycloalkenyl, heterocyclyl and aryl, each of which is optionally substituted with one or more R10 groups; each R10 is independently selected from halogen, OH, CN, NO2, COO-alkyl, aralkyl, SO2-alkyl, SO2-aryl, COOH, CO-alkyl, CO-aryl, NH2, NH-alkyl, N(alkyl)2, CF3, alkyl and alkoxy; X and Z are each independently CR11, and Y is selected from CR11 and N; and R11 is H or F; for use in treating a disorder associated with protein misfolding stress and in particular associated with accumulation of misfolded proteins.
    本发明涉及式(I)化合物或其同系物和/或药学上可接受的盐,其中:R1 是烷基、Cl、F 或 Br;R2 是 H 或 F;R3 选自 H 和烷基;R4 选自 H 和 C(O)R6;R5 是 H;或 R4 和 R5 连接形成杂环基团,该杂环基团任选被一个或多个 R10 基团取代;R6选自R7、OR7和NR8R9;R7、R8和R9各自独立地选自烷基、环烷基、芳基、环烯基、杂环烯基和芳基,其中每个基团都可选择被一个或多个R10基团取代;每个 R10 独立地选自卤素、OH、CN、NO2、COO-烷基、芳基、SO2-烷基、SO2-芳基、COOH、CO-烷基、CO-芳基、NH2、NH-烷基、N(烷基)2、CF3、烷基和烷氧基;X 和 Z 各自独立地为 CR11,Y 选自 CR11 和 N;R11 为 H 或 F;用于治疗与蛋白质错误折叠应激有关的疾病,特别是与错误折叠蛋白质的积累有关的疾病。
  • BENZYLIDENEGUANIDINE DERIVATIVES AND THERAPEUTIC USE FOR THE TREATMENT OF PROTEIN MISFOLDING DISEASES
    申请人:Medical Research Council
    公开号:EP2943467B1
    公开(公告)日:2016-07-13
  • US9682943B2
    申请人:——
    公开号:US9682943B2
    公开(公告)日:2017-06-20
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S,2'S)-(-)-[N,N'-双(2-吡啶基甲基]-2,2'-联吡咯烷双(乙腈)铁(II)六氟锑酸盐 (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 (1'R,2'S)-尼古丁1,1'-Di-N-氧化物 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸氯苯那敏-D6 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 韦德伊斯试剂 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非布索坦杂质66 非尼拉朵 非尼拉敏 雷索替丁 阿雷地平 阿瑞洛莫 阿扎那韦中间体 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 镉,二碘四(4-甲基吡啶)- 锌,二溴二[4-吡啶羧硫代酸(2-吡啶基亚甲基)酰肼]-